Richard Law
Stock Analyst at Goldman Sachs
(1.73)
# 2,047
Out of 4,412 analysts
47
Total ratings
18.18%
Success rate
-0.15%
Average return
Main Sectors:
Top Industries:
12 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MLYS Mineralys Therapeutics | Initiates: Buy | $30 | $11.87 | +152.74% | 5 | Apr 2, 2024 | |
| OLMA Olema Pharmaceuticals | Initiates: Buy | $24 | $9.95 | +141.21% | 4 | Apr 2, 2024 | |
| RCKT Rocket Pharmaceuticals | Initiates: Neutral | $39 | $21.98 | +77.43% | 1 | Apr 2, 2024 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Neutral | $62 | $42.49 | +45.92% | 1 | Apr 2, 2024 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Neutral | $11 | $5.33 | +106.38% | 4 | Aug 11, 2023 | |
| VERV Verve Therapeutics | Reiterates: Neutral | $31 | $6.16 | +403.25% | 2 | Aug 11, 2023 | |
| BEAM Beam Therapeutics | Maintains: Neutral | $46 → $47 | $21.38 | +119.83% | 3 | Aug 9, 2023 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $62 → $63 | $53.91 | +16.86% | 6 | Aug 8, 2023 | |
| KYMR Kymera Therapeutics | Maintains: Neutral | $36 → $37 | $33.37 | +10.88% | 8 | Aug 4, 2023 | |
| NTLA Intellia Therapeutics | Reiterates: Outperform | $76 | $20.76 | +266.09% | 6 | Jun 13, 2023 | |
| EDIT Editas Medicine | Maintains: Neutral | $15 → $14 | $5.32 | +163.16% | 3 | May 8, 2023 | |
| ARVN Arvinas | Reiterates: Outperform | $61 | $32.37 | +88.45% | 4 | May 8, 2023 |
Mineralys Therapeutics
Apr 2, 2024
Initiates: Buy
Price Target: $30
Current: $11.87
Upside: +152.74%
Olema Pharmaceuticals
Apr 2, 2024
Initiates: Buy
Price Target: $24
Current: $9.95
Upside: +141.21%
Rocket Pharmaceuticals
Apr 2, 2024
Initiates: Neutral
Price Target: $39
Current: $21.98
Upside: +77.43%
MoonLake Immunotherapeutics
Apr 2, 2024
Initiates: Neutral
Price Target: $62
Current: $42.49
Upside: +45.92%
Monte Rosa Therapeutics
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $5.33
Upside: +106.38%
Verve Therapeutics
Aug 11, 2023
Reiterates: Neutral
Price Target: $31
Current: $6.16
Upside: +403.25%
Beam Therapeutics
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $21.38
Upside: +119.83%
CRISPR Therapeutics AG
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $53.91
Upside: +16.86%
Kymera Therapeutics
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $33.37
Upside: +10.88%
Intellia Therapeutics
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $20.76
Upside: +266.09%
Editas Medicine
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $5.32
Upside: +163.16%
Arvinas
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $32.37
Upside: +88.45%